BFS International Operators Association’s Post

Day 2 of the 2024 TGA GMP Forum has started with the key topical area of Computerised Systems, Current and Future Considerations with Neale Baldwin and Alyce Maksoud #GMPForum #TGA #ISPE #ISPEAustralasia

Iofina CEO hails 'excellent' Q3 performance @iofinaplc #AIM #OTC #IOF #IOFNF. Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Tom Becker described the company's performance in the third as 'excellent' as it increased its iodine production and said it was planning further expansion with new plants. Output was 163.9 metric tonnes of crystalline iodine, up from 156.9 MT the previous year, with its new IO#10 plant beginning operations. Strong demand has increased iodine prices, a trend expected to continue into 2025. As part of its growth strategy, Iofina is set to begin construction on its next plant, IO#11, later this year. Plans for additional plants are already in... http://ow.ly/qhPS105Mfu0

Tell us what you would like to see on SEPIA. While we have numerous announced modules coming from existing and new partners, we would love to know what interests you most. Share this post and tag the manufacturer you want next on SEPIA. #SEPIA

Designing an Efficient, Predictable Global Post Approval Change System is presented by Anders Vinther as we move into afternoon concurrent sessions. He is presenting 8 specific and practical approaches to reduce the size of the PAC problem, which would facilitate less drug shortages and incentivize more continual improvement in the industry. #ISPE #ISPEEA24 #ISPEEuropeAnnual

#ShilpaMedicare: #USFDA issues form 483 with zero observations for Bio Analytical Lab, Unit 7, Nacharam, Hyderabad. #USFDA classifies Unit 7, #Nacharam, #Hyderabad as ‘no action indicated’, issues EIR #ShilpaMedicare #FDA #USFDA #483

The Programme of B.Sc PBBT in association with the GNCIIES and the GNIIC organized a Lecture Cum Expo on "Why our Medicinal Plant Knowledge is flattened?" on 12.08.2024 #bsc #lecture #expo #medicinalplants #medicinalherbs

Ananda Developments is pleased to announce that it has signed a contract with Southern Star Research (SSR), a leading Australian Contract Research Organization (CRO), to carry out a Phase 1 Pharmacokinetics (PK) study for our lead asset, MRX1.  This study will assess the PK profile, tolerability, and safety of MRX1 in healthy volunteers - marking an important step in MRX1's journey to market. Highlights: - Contract signed for Phase 1PK study - The clinical trial will investigate the PK profile, tolerability and safety of MRX1 in healthy volunteers - The data generated will inform future clinical trials in patients and form an integral part of any future regulatory applications, including with the MHRA in the United Kingdom or FDA in the United States - Collected data will form part of Ananda's MRX1 patent estate and wider intellectual property portfolio - Significant financial advantages of running the study in Australia, including an R&D Tax Incentive of up to 43.5% of eligible research and development costs Read the full announcement on our hub: https://lnkd.in/ey_MMdUc

Discover how and when to leverage the unique SAMDI approach to mass spec and ASMS during drug discovery in this free eGuide: https://okt.to/jfWuBQ

This study is a crucial step for the development of our MRX1 CBD-based drug candidate to become an MHRA (or EMA or FDA) authorised medicine. The data will also be added to our patent filings : deepening and widening the IP moat around our work. #cbd #cbddrugs

Eid is a time to celebrate, cherish memories, and strengthen bonds. Wishing you a wonderful Eid-ul-Fitr with your family and friends. Eid Mubarak !! #pharmacist #pharmastructure #eidmubarak #eid2024 #happyeid #Pharmaceuticalprojectconsultants #Turnkeyprojects #Pharmavalidation #Pharmacompanies #cleanrooms